Pulmonx Co. (NASDAQ:LUNG) Director Daniel P. Florin Buys 23,321 Shares

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) Director Daniel P. Florin acquired 23,321 shares of Pulmonx stock in a transaction that occurred on Thursday, June 5th. The shares were purchased at an average price of $3.06 per share, with a total value of $71,362.26. Following the purchase, the director now owns 117,231 shares in the company, valued at $358,726.86. This represents a 24.83% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pulmonx Stock Performance

Pulmonx stock traded up $0.20 during mid-day trading on Friday, reaching $3.17. 1,036,300 shares of the company traded hands, compared to its average volume of 316,044. The firm's fifty day moving average is $4.27 and its two-hundred day moving average is $5.95. The company has a market capitalization of $127.62 million, a price-to-earnings ratio of -2.20 and a beta of 0.52. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. Pulmonx Co. has a fifty-two week low of $2.83 and a fifty-two week high of $9.37.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.01. The business had revenue of $22.54 million for the quarter, compared to the consensus estimate of $22.03 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. On average, equities research analysts expect that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

Institutional Trading of Pulmonx

Several large investors have recently made changes to their positions in LUNG. BNP Paribas Financial Markets purchased a new stake in shares of Pulmonx in the 4th quarter valued at $43,000. ProShare Advisors LLC purchased a new stake in shares of Pulmonx in the 4th quarter valued at $72,000. Stifel Financial Corp purchased a new stake in shares of Pulmonx in the 4th quarter valued at $81,000. Vontobel Holding Ltd. purchased a new stake in Pulmonx during the first quarter worth $82,000. Finally, SG Americas Securities LLC boosted its holdings in Pulmonx by 27.0% during the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company's stock worth $106,000 after buying an additional 3,310 shares in the last quarter. 91.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on LUNG shares. Jefferies Financial Group started coverage on shares of Pulmonx in a research note on Monday, March 10th. They set a "buy" rating for the company. Citigroup cut their price target on shares of Pulmonx from $6.50 to $4.15 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Canaccord Genuity Group cut their price target on shares of Pulmonx from $16.00 to $15.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. Morgan Stanley started coverage on shares of Pulmonx in a research note on Monday, March 10th. They set an "equal weight" rating on the stock. Finally, D. Boral Capital restated a "buy" rating and set a $17.00 price target on shares of Pulmonx in a research note on Thursday, May 1st. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Pulmonx currently has a consensus rating of "Moderate Buy" and a consensus target price of $11.53.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.